GSK 
Welcome,         Profile    Billing    Logout  
 323 Products   957 Diseases   323 Products   1268 Trials   64372 News 


12345678910111213...750751»
  • ||||||||||  Rotarix (rotavirus vaccine) / GSK
    Journal, HEOR:  Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco. (Pubmed Central) -  May 17, 2024   
    However, costs of BRV-PV 1-dose vial were lower than HRV from the payer perspective, resulting in an ICER of approximately $328,376 per QALY, above the assumed cost effectiveness threshold of $3,500. Vaccination with a 2-dose schedule of HRV may be a cost-saving option and could lead to better health outcomes for children in Morocco versus 3-dose schedule rotavirus vaccines.
  • ||||||||||  Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Journal:  Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera. (Pubmed Central) -  May 16, 2024   
    Among the eleven antibodies, Sotrovimab was the only antibody to show broad neutralization ability against XBB.1.5...Additionally, XBB.1.5 seropositive convalescent sera displayed lower neutralization activity against EG.5, FL.1, and GE.1. Overall, our findings present enhanced immune evasion capacity of emerging XBB variants and emphasize the importance of continued monitoring of novel variants.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal, HEOR:  Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis. (Pubmed Central) -  May 16, 2024   
    In this cohort of almost half-a-million treatment-naive women with PMO, we observed clinically significant reductions in the risk of MOP, hip, NV, NHNV, and HV fractures for patients on denosumab compared with alendronate. Patients who remained on denosumab for longer periods of time experienced greater reductions in fracture risk.
  • ||||||||||  Galafold (migalastat) / Amicus
    Review, Journal:  A systematic review on safety and efficacy of Migalastat for the treatment of Fabry's disease. (Pubmed Central) -  May 16, 2024   
    Migalastat showed varied effects on enzyme activity and substrate levels, with gender-specific differences noted in GL-3 substrate activity and eGFR. Overall, it improved cardiac and renal outcomes similarly to enzyme replacement therapy, with a comparable safety profile.
  • ||||||||||  Bexsero (meningococcal group B vaccine) / GSK
    Journal:  Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020. (Pubmed Central) -  May 16, 2024   
    It is therefore important to test meningococcal serogroup B strains isolated from specific populations to estimate the percentage of bacterial strains that a vaccine can protect against (vaccine strain coverage). Meningococcal isolates were collected in Taiwan between 2003 and 2020, of which 134 were identified as serogroup B. We did further investigations on these isolates, including using a method (called gMATS) to predict vaccine strain coverage by the 4-component meningococcal serogroup B vaccine (4CMenB).
  • ||||||||||  valiltramiprosate (ALZ-801) / Alzheon
    Biomarker, Enrollment open:  APOLLOE4-LTE: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (clinicaltrials.gov) -  May 16, 2024   
    P3,  N=285, Enrolling by invitation, 
    Although our findings are generally consistent with other studies in the literature, larger long-term studies are needed to confirm our findings. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  GW-2580 / GSK
    Journal:  Identification of Selective Imidazopyridine CSF1R Inhibitors. (Pubmed Central) -  May 15, 2024   
    Drawing on previously described compounds, including GW2580 (4), we have discovered a novel series of compounds based on the imidazo[4,5-b]pyridine scaffold. Initial structure-activity relationship studies culminated in the identification of 36, a lead compound with potent CSF1R biochemical and cellular activity, acceptable in vitro ADME properties, and oral exposure in rat.
  • ||||||||||  Journal, Combination therapy:  Tafenoquine-Based Combination Therapies: A Step Toward Babesiosis Elimination. (Pubmed Central) -  May 15, 2024   
    Initial structure-activity relationship studies culminated in the identification of 36, a lead compound with potent CSF1R biochemical and cellular activity, acceptable in vitro ADME properties, and oral exposure in rat. No abstract available
  • ||||||||||  REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Journal:  Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies. (Pubmed Central) -  May 15, 2024   
    No abstract available The probability of emerging mutations arising in response to mAbs is significant, emphasizing the crucial need to investigate these mutations thoroughly and assess their impact on patients and the evolutionary trajectory of SARS-CoV-2.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Osteoporosis management in Australian aged care facilities: a mixed method study. (Pubmed Central) -  May 15, 2024   
    A need to raise awareness of aged care-specific consensus recommendations concerning vitamin D and calcium is evident. Facility protocols and procedures must be developed and implemented to ensure safe and effective use of denosumab.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Enrollment change, Trial termination:  Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome (clinicaltrials.gov) -  May 15, 2024   
    P4,  N=1, Terminated, 
    Current facile mitochondria-targeting modification with clinically applied drugs was promising for endowing traditional drugs with targeting, imaging, and improved potency in disease theranostics. N=10 --> 1 | Suspended --> Terminated; issues with supplier of strength testing equipment, presumed to go out of business
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Trial completion date, Trial primary completion date:  Botox or Botox With Esophageal Dilation in Patients With Achalasia (clinicaltrials.gov) -  May 15, 2024   
    P4,  N=50, Enrolling by invitation, 
    Phase classification: P2b --> P2 | N=200 --> 0 | Trial completion date: May 2025 --> Sep 2025 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Journal:  Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag. (Pubmed Central) -  May 13, 2024   
    P1/2
    Dosing restrictions due to thrombocytosis may cause insufficient iron chelation to decrease haem production and improve anaemia in most patients. Future work will focus on erythropoiesis dynamics in patients and use of haem synthesis inhibitors without an impact on other haematopoietic lineages.
  • ||||||||||  GSK3965193 / GSK
    Journal:  Mechanical overload induces TMJ disc degeneration via TRPV4 activation. (Pubmed Central) -  May 13, 2024   
    Future work will focus on erythropoiesis dynamics in patients and use of haem synthesis inhibitors without an impact on other haematopoietic lineages. Our findings suggest TRPV4 plays a pivotal role in the pathogenesis of mechanical overload-induced TMJ disc degeneration and may be a promising target for the treatment of degenerative changes of the TMJ disc.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Local radiographic risk factors for MRONJ in osteoporotic patients undergoing tooth extraction. (Pubmed Central) -  May 13, 2024   
    Our findings suggest TRPV4 plays a pivotal role in the pathogenesis of mechanical overload-induced TMJ disc degeneration and may be a promising target for the treatment of degenerative changes of the TMJ disc. Tooth extraction sites showing radiographic signs of chronic dental infection are prone to MRONJ.
  • ||||||||||  Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
    Journal:  Assessing herpes zoster vaccine efficacy in patients with diabetes: A community-based cohort study. (Pubmed Central) -  May 13, 2024   
    Subgroup analyses across age, sex, and follow-up duration also showed no significant differences. These findings underscore the lack of a significant benefit from HZ vaccination in newly diagnosed diabetes patients aged over 50, highlighting the necessity for further prospective research.
  • ||||||||||  Review, Journal:  Advances in pharmacotherapy for myelofibrosis: what is the current state of play? (Pubmed Central) -  May 13, 2024   
    These findings underscore the lack of a significant benefit from HZ vaccination in newly diagnosed diabetes patients aged over 50, highlighting the necessity for further prospective research. Nowadays three more JAKi, fedratinib, pacritinib and momelotinib, are available for both ruxolitinib-resistant and na
  • ||||||||||  Review, Journal:  Biologic therapies for severe asthma with persistent type 2 inflammation. (Pubmed Central) -  May 13, 2024   
    Biologic asthma therapies are very effective in improving symptoms, and reducing the rate of exacerbations and use of oral corticosteroids, in people with severe asthma and persistent type 2 inflammation. Inhaled corticosteroid treatment should be continued in people using a biologic therapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target. (Pubmed Central) -  May 11, 2024   
    Bisphosphonates and denosumab significantly reduced the risk of vertebral fractures in patients with both obesity and T2DM...It is important to recognize elevated fracture risk and osteoporosis in obese and T2DM patients, as they are currently considered low risk and tend to be underdiagnosed and undertreated. The implementation of better diagnostic tools, including trabecular bone score, lumbar spine BMD/body mass index (BMI) ratio, and microRNAs to predict bone fragility, could improve fracture prevention in this patient group.
  • ||||||||||  benzimidazole carboxamides / GSK
    Journal:  Design, Synthesis and Biological Activity of Novel Methoxy- and Hydroxy-Substituted N-Benzimidazole-Derived Carboxamides. (Pubmed Central) -  May 11, 2024   
    This work presents the design, synthesis and biological activity of novel N-substituted benzimidazole carboxamides bearing either a variable number of methoxy and/or hydroxy groups...However, their antiproliferative activity was not related to their ability to inhibit oxidative stress nor to their ability to induce it. Compound 8 with two hydroxy and one methoxy group on the phenyl ring showed the strongest antibacterial activity against the Gram-positive strain E. faecalis (MIC = 8 ?M).
  • ||||||||||  GSK2816126 / GSK
    Journal:  Identification and functional analysis of the hub Ferroptosis-Related gene EZH2 in diabetic kidney disease. (Pubmed Central) -  May 11, 2024   
    Compound 8 with two hydroxy and one methoxy group on the phenyl ring showed the strongest antibacterial activity against the Gram-positive strain E. faecalis (MIC = 8 ?M). Overall, our data shouwed that histone H3K27 methyltransferase EZH2 could regulate the renal tubular epithelial cell ferroptosis by suppressing SLC7A11 in DKD, which may serve as a credible reliable indicator for diagnosing DKD and a potential target for treatment.
  • ||||||||||  GW-2580 / GSK
    Journal:  CSF1R blockade slows progression of cerebral hemorrhage by reducing microglial proliferation and increasing infiltration of CD8 (Pubmed Central) -  May 11, 2024   
    Using a colony-stimulating factor-1 receptor antagonist (GW2580), we observed that inhibition of microglia proliferation significantly ameliorated neurobehavioral deficits, attenuated cerebral edema, and reduced hematoma volume after ICH...Thus, inhibition of microglial proliferation offers a new perspective for clinical translation. The cross-talk between multiple cells involved in the regulation of the inflammatory response highlights the comprehensive nature of neuroimmunomodulation.